Skip to main content
padlock icon - secure page this page is secure

Transcriptomics in Cancer - Stages Toward Patents in Biomarkers?

Buy Article:

$68.00 + tax (Refund Policy)

Transcriptomics in cancer is one of the newly researched domains because it mirrors all the post genomic variation. In spite of extended studies, carcinogenesis still remains a highly unknown process due to multiple factors that are involved in cancer initiation. Carcinogenesis is a complex network of processes starting from genetic alterations, accumulation of mutation, going through epigenetic alteration and ending with proteomic alterations that can lead to uncontrolled proliferation, differentiation, invasion, and ultimately metastasis. From gene to protein, cancer cells can be studied at transcriptomic level in order to detect new relevant biomarkers and/or new drug targets. We highlight herein some of the cancers that were lately subjects for transcriptomic biomarkers patents, among which: breast, prostate, oral, brain, pancreatic cancer and cutaneous melanoma. A glimpse of the up-dated methodology and analysis used in transcriptomics is presented along with the recent patents that claim transcriptomics biomarkers.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Biomarkers; brain cancers; breast cancer; cancer; cutaneous melanoma; embryonic stage; oral cancer; patents; prostate cancer; transcriptomics

Document Type: Research Article

Publication date: May 1, 2012

More about this publication?
  • Recent Patents on Biomarkers publishes review and research articles, and guest edited thematic issues on important recent patents on biomarkers. The coverage includes novel biomarkers in basic, medical, environmental, and pharmaceutical research. A selection of important and recent patents on biomarkers is also included in the journal. The journal is essential reading for all researchers involved in biomarker research and discovery. The journal also covers recent research (where patents have been registered) in fast emerging patent biomarker applications; discovery and validation are covered for drug discovery, clinical development and molecular diagnostics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more